Patients
Bio-Path is conducting multiple clinical studies in adults with hematologic malignancies or solid tumors.
Abbreviated study descriptions are below. For more detailed inclusion and exclusion criteria and a list of sites where the study is enrolling, please visit the appropriate clinicatrials.gov listing.
Acute Myeloid Leukemia (AML)
Study stage: Phase 2
Recruiting status: open
Candidate: prexigebersen (BP1001)
Other medications: Venetoclax, Decitabine
Patient characteristics:
untreated AML patients; refractory/relapsed AML patients; venetoclax resistant or intolerant AML patients
Age: 18yr and older
Advanced or Recurrent Solid Tumors
Study stage: Phase 1/1b
Recruiting status: not yet recruiting
Candidate: BP-1001-A
Other medications: paclitaxel
Patient characteristics:
patients with advanced or recurrent solid tumors with a focus on ovarian or endometrial tumors in Phase 1b
Age: 18yr and older
Advanced Lymphoid Malignancies
Study stage: Phase 1
Recruiting status: open
Candidate: prexigebersen-A (BP1001-A)
Other medications: none
Patient characteristics:
patients with relapsed or refractory lymphoid malignancies such as (but not limited to) mantle cell lymphoma, PTCL, follicular lymphoma, Hodgkin lymphoma and DLBCL
Age: 18yr and older
Refractory or Relapsed AML
Study stage: Phase 1/1b
Recruiting status: not yet recruiting
Candidate: BP1002
Other medications: decitabine
Patient characteristics:
patients with refractory or relapsed AML
Age: 18yr and older
